Abstract:BACKGROUNDThe objective of this study was to investigate the antitumor activity of selectively expanded gammadelta T cells in tumor-infiltrating lymphocytes (gammadeltaTILs) or tumor ascites lymphocytes (gammadeltaTALs) from patients with colorectal and ovarian epithelial carcinoma (OEC) in vitro and in vivo.METHODSgammadeltaTILs/TALs were expanded by the solid-phase antibody method; their cytolytic and proliferative activities in vitro were detected by the MTT method and 3H-TdR incorporation and their effect in vivo was evaluated by the nude mice model.RESULTSExpanded gammadeltaTILs from colorectal tumors demonstrated marked cytotoxicities to allogeneic human colon adenocarcinoma HR8348 and lymphoma Daudi cells, as well as xenogeneic murine thymoma EL-4 cell lines. Cytokines, including IL-2, IL-4, IL-12, IL-15, TNF-alpha and INF-gamma, could promote the cytotoxicities of gammadeltaTILs to tumor cells, whereas IL-10, GM-CSF and TFG-beta had no effect on such killing activities. Rested gammadeltaTILs could proliferate strongly in response to mitomycin C-treated Daudi and EL-4 tumor cells, but not to HR8348 tumor cells, suggesting that the latter might possess only cytotoxicity-related antigen recognized by gammadeltaTILs. Either alphabetaTILs or gammadeltaTILs from patients with OEC displayed cytotoxicities to allogeneic or autologous OEC cell lines at a similar strength in vitro. Transferring gammadeltaTILs into Daudi cell-bearing BALB/c nude mice with an injection of IL-2 was able to maintain a high survival rate of the mice for 30 days, when compared with mice treated with alphabetaTILs or without any treatment (p < 0.05). Without coinjection of IL-2, after 3 months of Daudi tumor inoculation, a high survival rate was observed in gammadeltaTIL-treated mice. Similarly, adoptive gammadeltaTALs from the ascites of patients with OEC transferred into nude mice displayed a stronger antitumor response to OEC SKOV3 cells than alphabetaTALs in vivo. Tumor volumes in gammadeltaTAL-treated mice were smaller than in alphabetaTAL-treated or non-TAL-treated mice within the period from day 23 to day 50 after tumor inoculation (p < 0.05). Fifty days after SKOV3 tumor inoculation, a decreasing trend of carcinogenic rate was observed in gammadeltaTAL-treated nude mice.CONCLUSIONTaken together, our results suggest that gammadeltaT cells could be a new candidate for adoptive immunotherapy in the future treatment of patients with cancer.

Expansion and Immunological Study of Human Tumor Infiltrating Gamma/Delta T Lymphocytes in Vitro

Expansion and Immunological Study of Human Tumor Infiltrating Gamma/Delta T Lymphocytes in vitro<sup>1</sup>

Antitumor Activity of Expanded Human Tumor-Infiltrating Gammadelta T Lymphocytes.

Potential Regulatory Role of in Vitro-Expanded Vδ1 T Cells from Human Peripheral Blood

Effect of γδT Cells in Tumor

Identification of Human T Cell Receptor Γδ-Recognized Epitopes/Proteins Via CDR3δ Peptide-based Immunobiochemical Strategy

Anti-γδ TCR Antibody-Expanded Γδ T Cells: a Better Choice for the Adoptive Immunotherapy of Lymphoid Malignancies

Generation Of Human Regulatory Gamma Delta T Cells By Tcr Gamma Delta Stimulation In The Presence Of Tgf-Beta And Their Involvement In The Pathogenesis Of Systemic Lupus Erythematosus

Soluble Anti-Tcr Γδ Stimulates Expansion of Human Peripheral Blood Γδ T Cells and Its Culture and Storage.

Isolation and expansion of pure and functional γδ T cells

Exploring γδ T cells for use in non-MHC restricted immunotherapy

Research Progress of γδT Cells in Tumor Immunotherapy

Isolation and expansion of murine γδ T cells from mouse splenocytes

Human Gamma Delta T-Cell Subsets And Their Involvement In Tumor Immunity

Ex Vivo Expanded Human Circulating V Delta 1 Gamma Delta T Cells Exhibit Favorable Therapeutic Potential for Colon Cancer

Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer

Rapamycin Together with TGF-β1, IL-2 and IL-15 Induces the Generation of Functional Regulatory Γδt Cells from Human Peripheral Blood Mononuclear Cells

Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future

Human Γδt-Cell Subsets and Their Involvement in Tumor Immunity.

Improving the <i>ex vivo</i> expansion of human tumor-reactive CD8+T cells by targeting toll-like receptors

[Research Progress of Gammadelta T Cell-Based Immunotherapy].